Skip to main content

Table 2 Baseline clinical features of pediatric- and adult-onset systemic lupus erythematosus (pSLE and aSLE) patients based on osteopontin (OPN) quartiles*

From: Plasma levels of osteopontin identify patients at risk for organ damage in systemic lupus erythematosus

  pSLE   aSLE  
  OPNlo OPNhi P-value OPNlo OPNhi P-value
Current prednisone dosage, mg/day, median (range) 10 (0, 60) 30 (0, 40) 0.6 5 (0, 5) 12.5 (0, 60) 0.1
High cumulative prednisone dose, patients, number (%) 2 (13) 8 (73) 0.01 1 (25) 3 (27) 0.3
Current immunosuppressive use, patients, number (%) 7 (44) 7 (64) 0.6 2 (25) 5 (46) 0.6
Renal involvement, patients, number (%) 8 (50) 8 (73) 0.4 0 (0) 4 (36) 0.5
Disease duration, years 2.3 ± 2.7 4.5 ± 3.5 0.2 8.5 ± 12.3 11.8 ± 7.6 0.7
SDI, median (range) 0 (0, 3) 2 (0, 5) 0.01 0 (0, 2) 0 (0, 2) 0.9
SLEDAI, median (range) 2 (0, 8) 2 (0,16) 0.3 2 (0, 8) 4 (0, 8) 0.6
ESR 18 ± 7 54 ± 28 0.01 8 ± 6 45 ± 35 0.1
C3 100 ± 32 95 ± 40 0.7 115 ± 15 89 ± 24 0.9
C4 15 ± 5   0.7 22 ± 3.3 19.2 ± 5.5 0.3
αdsDNA, % patients negative/% patients positive 46/8 40/40 < 0.0001 100/0 43/29 < 0.0001
αRBP, % patients positive 25 45 0.003 20 43 0.0005
  1. *Except where otherwise indicated, values are expressed as mean ± standard deviation. The lowest and highest quartile of OPN (OPNlo and OPNhi) were defined as circulating plasma OPN levels < 7.8 ng/ml (n = 16 in pSLE and 11 in aSLE) or > 19.1 ng/ml (n = 4 in pSLE and 11 in aSLE), respectively. High cumulative prednisone dose was defined as > 300 mg/kg in pSLE and > 20 g in aSLE. SDI, Systemic Lupus International Collaborating Clinics/American College of Rheumatology (SLICC/ACR) damage index; SLEDAI, SLE, disease activity index; ESR, erythrocyte sedimentation rate; C3 and C4, complement 3 and 4; αdsDNA, anti-dsDNA antibody; borderline positive results were not included. αRBP, anti-RNA binding protein antibody.